Sector News

How China is transforming the biotech industry: Brainstorm Health

October 8, 2019
Life sciences

Fortune sat down with Brad Loncar, a biotech investor who specializes in cancer immunotherapy, at our offices last week. Loncar runs both a U.S.-based index fund for cancer drug companies and, more recently, launched another one focused on China.

It was a fascinating conversation that covered everything from the U.S. oncology field to the shifting global dynamics of cancer drug development.

It would be difficult to capture the entire conversation in a single missive. But I want to highlight one particularly interesting part—the evolving nature of China’s biotech industry, especially when it comes to the “biologic” drugs which have become a hotbed of cancer therapy innovation.

“The Chinese FDA is trying to replicate the U.S. FDA,” Loncar tells Fortune, noting that about half of the biggest, global biopharma IPOs last year occurred in China.

This presents a major shift for China. Brand name biologic drugs (the kind that are derived from biological, rather than chemical, material and are therefore much more difficult to produce) make up nearly 80% of the top-sellers in the U.S.; China, traditionally, has been much more focused on the generic market.

That’s changing. “They want to go from becoming just a manufacturer to a true innovator,” says Loncar.

The Chinese government is trying to make that happen through a series of policy shifts, including more stringent drug development standards in line with other nations (including the U.S.), new trade policies, and revamped stock market rules meant to fuel funds to early-stage drug companies.

Just how effective could these efforts prove? WuXi Biologics, a Chinese company whose technology platforms help produce a staggering 12% of the world’s biologic drugs, is aggressively expanding into American and European markets.

And here’s the kicker: Chinese companies could very well undercut American firms on pricing if their products pass muster and reach the U.S. market. If that’s really the wave of the future, U.S. drug makers are on notice.

By Sy Mukherjee

Source: Fortune

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.